Analyst Price Target is $29.67
▲ +295.56% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Lumos Pharma in the last 3 months. The average price target is $29.67, with a high forecast of $35.00 and a low forecast of $24.00. The average price target represents a 295.56% upside from the last price of $7.50.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in Lumos Pharma.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.